Algae Expression of Recombinant Growth Factors Without Endotoxins

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for producing recombinant growth factors such as EGF, aFGF, and bFGF using mammalian cells, bacteria, and yeast face high costs, safety concerns due to pathogen and endotoxin risks, and scalability issues, with complex protein structures often requiring additional assembly steps.

Innovation Solution

A novel method using algae-based expression systems to produce growth factors from the nuclear or chloroplast genome, utilizing expression vectors and AI-assisted molecular design to enhance thermostability, eliminating pathogen and endotoxin risks, and enabling efficient assembly of complex structures.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If mammalian cell lines are used to produce growth factors, then high-quality growth factors with proper folding and dimerization are obtained, but production costs exceed $1,000 per milligram due to low expression levels

Engineering Contradiction:

Improveprotein folding and dimerization qualityVSAvoidexpression level

Core Design Contradiction:

Manufacturing precisionVSProductivity

Solution Approach 1:

The patent uses algae as a disposable, inexpensive production platform that can be rapidly grown and harvested. The algae cells serve as temporary factories for growth factor production, then are discarded after extraction, eliminating the need for expensive, long-lived mammalian cell lines while maintaining production efficiency

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent changes the expression parameters by using algae-specific promoters and optimizing cultivation conditions for algae. This includes controlling light exposure, nutrient composition, and growth phase to maximize growth factor production while maintaining proper protein folding and assembly

Inventive Principle:

Principle #35Parameter changes

2Manufacturing precision

If mammalian cell lines are used for growth factor production, then proper protein assembly is achieved, but pathogen contamination risk increases

Engineering Contradiction:

Improveprotein assembly capabilityVSAvoidpathogen contamination risk

Core Design Contradiction:

Manufacturing precisionVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the protein assembly capability from mammalian cells and transfers it to algae through genetic engineering. The growth factor genes are inserted into algae, which then produce the proteins with proper folding and assembly, eliminating the pathogen risk associated with mammalian cell lines while retaining the necessary biochemical functions

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses algae as an intermediary organism that bridges the gap between simple bacterial systems and complex mammalian systems. Algae provide a eukaryotic cellular environment capable of proper protein assembly without the pathogen risks of mammalian cells, serving as a safe intermediate production platform

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If bacterial systems are used to produce growth factors, then production cost is reduced, but endotoxin contamination and inability to assemble complex structures occur

Engineering Contradiction:

Improveproduction cost efficiencyVSAvoidendotoxin contamination

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent copies the beneficial features of bacterial systems (low cost, high yield) while eliminating their harmful features (endotoxin production). By using algae instead of bacteria, the system maintains economic efficiency through rapid growth and easy harvesting while avoiding endotoxin contamination entirely, as algae do not produce endotoxins

Inventive Principle:

Principle #26Copying

4Manufacturing precision

If mammalian systems are used for growth factor production, then proper refolding and dimerization occur, but scalability is limited

Engineering Contradiction:

Improverefolding and dimerization efficiencyVSAvoidscalability

Core Design Contradiction:

Manufacturing precisionVSProductivity

Solution Approach 1:

The patent moves the production system to a new dimension by using photosynthetic algae that can be cultivated in photobioreactors or open ponds. This allows for large-scale production through surface-area-based cultivation rather than volume-based mammalian cell culture, enabling much greater scalability while maintaining proper protein assembly through eukaryotic cellular machinery

Inventive Principle:

Principle #17Another dimension (Dimensionality change)

Data Source

PatentUS20250361278A1Recombinant production of growth factors in algae for cell culture applications

Publication Date: 2025.11.27 PHYCIN INC

AI summary

The present invention provides a method for producing recombinant growth factors using an algal expression system, which offers advantages over traditional platforms, and the algae-derived growth factors can be used to formulate cell culture media for mammalian cells without the risk of pathogen contamination or endotoxins.